Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized treatment for people with relapsed and refractory forms of leukemia, lymphoma and multiple myeloma. However, patients who receive CAR-T therapy often develop adverse immune reactions, sometimes severe enough to require intensive care. Pharmacists who help manage these patients in the ICU need to intervene quickly with treatments that can dampen these reactions and ensure optimal outcomes.
“These therapies